Table 1. Clinical and transplant characteristics of all patients and comparison between MDS and sAML patients.
| Characteristic | All | MDS | sAML | P |
|---|---|---|---|---|
| No. (%) | 304 | 144 (47) | 160 (53) | |
| Patient age, years | 1.0 | |||
| Median | 58 | 56 | 59 | |
| Range | 19-75 | 19-74 | 29-75 | |
| Patient sex | .74 | |||
| Male - no. (%) | 193 (63) | 90 (63) | 103 (64) | |
| Female - no. (%) | 111 (37) | 54 (37) | 57 (36) | |
| Disease status at transplant | .006 | |||
| Untreated or in CR- no. (%) | 170 (56) | 96 (67) | 74 (46) | |
| Treated but not in CR - no. (%) | 120 (39) | 48 (33) | 72 (45) | |
| Missing – no. (%) | 14 (5) | 0 (0) | 14 (9) | |
| Cytogenetic risk (according IPSS-R) | .53 | |||
| Very good - no. (%) | 2 (1) | 2 (1) | 0 (0 | |
| Good – no. (%) | 133 (44) | 64 (45) | 69 (43) | |
| Intermediate - no. (%) | 51 (17) | 21 (15) | 30 (19) | |
| Poor - no. (%) | 85 (28) | 42 (29) | 43 (27) | |
| Very poor – no. (%) | 11 (3) | 5 (3) | 6 (3) | |
| Missing - no. (%) | 22 (7) | 10 (7) | 12 (8) | |
| WBC count | 0.64 | |||
| Median (x109/µl) | 2.85 | 2.85 | 2.85 | |
| Range (x109/µl) | 0.2-293 | 0.5-293 | 0.2-261 | |
| Missing - no. (%) | 106 (35) | 52 (36) | 54 (34) | |
| Hemoglobin | 0.021 | |||
| Median (g/dl) | 9.3 | 8.9 | 9.9 | |
| Range (g/dl) | 2.6-15 | 4.6-13.7 | 2.6-15 | |
| Missing - no. (%) | 107 (35) | 52 (36) | 55 (34) | |
| Platelets | 0.073 | |||
| Median (x109/µl) | 16.2 | 23.2 | 13.6 | |
| Range (x109/µl) | 0.5-395 | 0.5-395 | 0.5-347 | |
| Missing - no. (%) | 105 (35) | 52 (36) | 53 (33) | |
| Cytopenias in peripheral blood | 0.75 | |||
| 0-1 cytopenia - no. (%) | 82 (27) | 37 (26) | 45 (28) | |
| 2-3 cytopenias - no. (%) | 116 (38) | 55 (38) | 61 (38) | |
| Missing - no. (%) | 106 (35) | 52 (36) | 54 (34) | |
| Bone marrow blasts before alloTx | <0.001 | |||
| Median (%) | 5 | 6 | 4 | |
| Range (%) | 0-80 | 0-19 | 0-80 | |
| Missing - no. (%) | 34 (11) | 19 (13) | 15 (9) | |
| WHO classification | n.a. | |||
| RA - no. (%) | 8 | 8 | ||
| RARS - no. (%) | 4 | 4 | ||
| RCMD - no. (%) | 35 | 35 | ||
| RAEB-1 - no. (%) | 30 | 30 | ||
| RAEB-2 - no. (%) | 59 | 59 | ||
| MDS-U - no. (%) | 1 | 1 | ||
| sAML - no. (%) | 160 | 160 | ||
| Missing - no. (%) | 7 | 7 | ||
| HCT-CI score | 0.91 | |||
| 0-2 - no. (%) | 192 (63) | 92 (64) | 100 (63) | |
| > 2 - no. (%) | 110 (36) | 52 (36) | 58 (36) | |
| Missing - no. (%) | 2 (1) | 0 (0) | 2 (1) | |
| Donor match | .87 | |||
| MRD - no. (%) | 71 (23) | 34 (24) | 37 (23) | |
| MUD - no. (%) | 171 (56) | 79 (55) | 92 (58) | |
| MMUD - no. (%) | 62 (21) | 31 (21) | 31 (19) | |
| Donor sex | .11 | |||
| Male - no. (%) | 208 (68) | 105 (73) | 103 (64) | |
| Female - no. (%) | 96 (32) | 39 (27) | 57 (36) | |
| Stem Cell source | .21 | |||
| PBSC - no. (%) | 288 (95) | 133 (93) | 155 (97) | |
| Bone marrow - no. (%) | 13 (4) | 9 (6) | 4 (2) | |
| Cord Blood - no (%) | 3 (1) | 2 (1) | 1 (1) | |
| CMV status | .44 | |||
| D pos/P pos - no. (%) | 108 (36) | 53 (37) | 55 (34) | |
| D pos/P neg - no. (%) | 45 (15) | 16 (11) | 29 (18) | |
| D neg/P neg - no. (%) | 94 (31) | 46 (32) | 48 (30) | |
| D neg/P pos - no. (%) | 50 (16) | 23 (16) | 27 (17) | |
| Missing - no. (%) | 7 (2) | 6 (4) | 1 (1) | |
| Conditioning | .93 | |||
| Myeloablative - no. (%) | 47 (15) | 22 (15) | 25 (16) | |
| Reduced intensity - no. (%) | 257 (85) | 122 (85) | 135 (84) | |
| Acute GvHD | .24 | |||
| Yes - no. (%) | 158 (52) | 80 (56) | 78 (49) | |
| No - no. (%) | 146 (48) | 64 (44) | 82 (51) | |
| Acute GvHD stage (n=158) | .16 | |||
| °I or °II - no. (%) | 107 (35) | 50 (35) | 57 (36) | |
| °III or °IV - no. (%) | 51 (17) | 30 (21) | 21 (13) | |
| Chronic GvHD | .23 | |||
| Yes - no. (%) | 118 (39) | 61 (42) | 57 (36) | |
| No - no. (%) | 186 (61) | 83 (58) | 103 (64) | |
| Chronic GvHD stage (n=118) | .016 | |||
| Limited - no. (%) | 52 (17) | 32 (22) | 20 (13) | |
| Extensive - no. (%) | 55 (18) | 21 (15) | 34 (21) | |
| Missing - no. (%) | 11 (4) | 8 (6) | 3 (2) | |
Abbreviations: MDS, myelodysplastic syndromes; sAML, secondary acute myeloid leukemia; no., number; CR, complete remission; IPSS-R, Revised International Prognostic Scoring System; WBC, white blood cell; alloTx, allogeneic stem cell transplantation; WHO, world health organization; RA, refractory anemia, RARS, refractory anemia with ring sideroblasts; RCMD, refractory cytopenia with multilineage dysplasia; RAEB, refractory anemia with excess of blasts; HCT-CI, hematopoietic cell transplantation comorbidity index; MRD, matched related donor; MUD, matched unrelated donor; MMUD, mismatched unrelated donor; PBSC, peripheral blood stem cells; D, donor; P, patient; neg, negative; pos., positive; CMV, cytomegalovirus; GvHD, graft-versus-host-disease.